Business
BioElectronics Vice President of Sales Discusses Opioids and the Alternative Drug Free ActiPatch® Pain Therapy
BioElectronics Vice President of Sales Discusses Opioids and the Alternative Drug Free ActiPatch® Pain Therapy.
About this update from Bioelectronics Corp.
[{"type":"text","content":"\n\n PHOENIX, Jan. 22, 2018 (GLOBE NEWSWIRE) -- The Uptick Newswire “Stock Day” podcast keeps investors up to date on the latest penny stock news by bringing transparency in the micro-cap side of the market. Connect with “Stock Day” and to over 600+ CEO interviews on the OTC, Pink Sheets and micro-cap news from around the world by following Stock Day’s YouTube, Google Play, and iTunes. Everett Jolly, CEO and host of “Stock Day” welcomes Keith Nalepka, Vice President of Sales and Marketing for BioElectronics Corporation (OTC Pink:BIEL) (the “Company”). \n Mr. Jolly was excited to point out that the stock price of BioElectronics Corporation is trading around .0009 cents, up almost 40% from the past time the Company made an appearance on “Stock Day”. “What’s going on?” Mr. Jolly asks.  BioElectronics’ Vice President of Sales and Marketing explains that ActiPatch® the Company’s drug free medical device alternative to opioids has been approved by the respected United Kingdom’s National Health Service for reimbursement and that the Company and Care Pharmacies have launched its “Pharmacists Pain Management Consultations” in the US to help mitigate the drug crisis. In its studies of UK patients, ActiPatch decreased medication use by 36% and professional office visits 58%.  These studies show good evidence for reducing the need for opioid medications as well as the special needs costs of chronic pain suffers. Nalepka is hopeful that this clinical support will encourage UK, US, and other physicians to recommend the ActiPatch® as well as help springboard sales of the FDA cleared nonprescription device. “​ActiPatch®​is doing what it has always done providing safe and superior pain relief! My past success in pain products and retail leads me to believe that to get products into retail is a challenge for small companies but ActiPatch is a strong contender.” Anticipating a perfect storm, he states that “2018 is going to be a transformational year for this Company.”  Listen to the full plan of execution here: https://upticknewswire.com/featured-interview-vp-of-sales-keith-nalepka-of-bioelectronics-corp-otcpink-biel .To listen to the interview in its entirety plea...